Calypso Biotech BV: DGAP-News: CALYPSO BIOTECH SA: Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases
DGAP-News: CALYPSO BIOTECH SA / Key word(s): Research Update/Study CALYPSO BIOTECH SA: Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclon...
Read full article »
Calypso Biotech is a Netherlands-based biotechnology company that researches and develops monoclonal antibodies for the treatment of autoimmune diseases.
Read more